Why Acadia Pharmaceuticals Stock Is on Fire Today
Shares of mid-cap drugmaker Acadia Pharmaceuticals (NASDAQ: ACAD) rose by as much as 13% in pre-market trading today. The biopharma's stock is jumping in response to a presentation at the 12th Clinical Trials on Alzheimer's Disease meeting Wednesday covering the latest trial results for Nuplazid's late-stage dementia-related psychosis trial known as Harmony.
Earlier this year, Acadia announced that Harmony had been halted early because patients on placebo were more than twice as likely to show worsening symptoms compared to those on Nuplazid. This latest update provided additional information on the drug's all-important safety profile in this patient population.
Image source: Getty Images.
Source Fool.com
